Brenner, I. R., Flanagan, C. F., Penazzato, M., Webb, K. A., Horsfall, S. B., Hyle, E. P., Abrams, E., Bacha, J., Neilan, A. M., Collins, I. J., Desmonde, S., Crichton, S., Davies, M.-A., Freedberg, K. A., & Ciaranello, A. L. (2024). Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis. The Lancet Global Health, 12(12), e2068–e2079. https://doi.org/10.1016/s2214-109x(24)00381-4

Christopoulos, K. A., Smith, M. B., Pareek, P., Dawdani, A., Erguera, X. A., Dance, K. V., Walker, R. S., Grochowski, J., Mayorga‐Munoz, F., Hickey, M. D., Johnson, M. O., Sauceda, J., Gutierrez, J. I., Montgomery, E. T., Colasanti, J. A., Collins, L. F., McNulty, M. C., & Koester, K. A. (2024). Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics. Journal of the International AIDS Society, 27(11). Portico. https://doi.org/10.1002/jia2.26394

Rael, C. T., Das, D., Porter, J., Lopez-Ríos, J., Abascal, E., Dolezal, C., Vaughn, M. P., Giffenig, P., Lopez, J. M., Stonbraker, S., Sun, C., Velasco, R. A., Bitterfeld, L., Bockting, W. O., & Bauermeister, J. (2024). Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study. Journal of the Association of Nurses in AIDS Care, 35(5), 437–449. https://doi.org/10.1097/jnc.0000000000000488

Abrams, E. J., Jao, J., Madlala, H. P., Zerbe, A., Catalano, P., Gerschenson, M., Goedecke, J. H., Gomba, Y., Josefson, J., Kurland, I. J., Legbedze, J., McComsey, G. A., Matyesini, S., Mukonda, E., Robinson, D., & Myer, L. (2024). An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol. PLOS ONE, 19(8), e0307296. https://doi.org/10.1371/journal.pone.0307296

Navi, B. B., Zhang, C., Miller, B., Cushman, M., Kasner, S. E., Elkind, M. S. V., Tirschwell, D. L., Longstreth, W. T., Kronmal, R. A., Beyeler, M., Elm, J., Zweifler, R. M., Tarsia, J., Cereda, C. W., Bianco, G., Costamagna, G., Michel, P., Broderick, J. P., Gladstone, D. J., … Streib, C. (2024). Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke. JAMA Neurology, 81(9), 958. https://doi.org/10.1001/jamaneurol.2024.2404

Plumber, S. A., Tate, T., Al-Ahmadie, H., Chen, X., Choi, W., Basar, M., Lu, C., Viny, A., Batourina, E., Li, J., Gretarsson, K., Alija, B., Molotkov, A., Wiessner, G., Lee, B. H. L., McKiernan, J., McConkey, D. J., Dinney, C., Czerniak, B., & Mendelsohn, C. L. (2024). Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-50678-2

Sprinzen, L., Garcia, F., Mela, A., Lei, L., Upadhyayula, P., Mahajan, A., Humala, N., Manier, L., Caprioli, R., Quiñones-Hinojosa, A., Casaccia, P., & Canoll, P. (2024). EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor. Cells, 13(3), 219. https://doi.org/10.3390/cells13030219

Kim, J. S., Murray, S., Yow, E., Anstrom, K. J., Kim, H. J., Flaherty, K. R., Martinez, F. J., & Noth, I. (2024). Comparison of Pirfenidone and Nintedanib. CHEST, 165(5), 1163–1173. https://doi.org/10.1016/j.chest.2023.11.035